FOLH1 and neoplasm: Favourable results in a phase 3 therapeutic trial, using [177Lu]Lu-PSMA-617, were recently reported [13], and several 18F- and 68 Ga-labelled agents are finding widespread use for diagnostic imaging, with high tumour-to-background ratios allowing for disease detection in most cases of prostate cancer (> 90%) [14–27].